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Background: Fatigue is a common symptom of chronic hepatitis C virus (cHCV) infection and a common side
effect of interferon-based treatment for cHCV. This study provides confirmatory evidence of the reliability and
validity of the Fatigue Severity Scale (FSS) to document fatigue in cHCV research and identifies values that indicate
clinically important differences in FSS to aid in interpreting fatigue in cHCV clinical trials.
Methods: The study used data from two double-blind, randomized, placebo-controlled, Phase IIb trials evaluating
the efficacy and safety of simeprevir plus peginterferon-α/ribavirin in treatment-naïve (PILLAR, n = 386) and
treatment-experienced patients (ASPIRE, n = 462) with cHCV infection. Patients completed the FSS and EuroQoL 5
dimension questionnaire (EQ-5D) at baseline and at regular intervals throughout both trials. Reliability was assessed
using Cronbach’s coefficient α at Week 24 (internal consistency reliability) and intraclass correlation (ICC) between
FSS at Weeks 12 and 24 in stable patients (<0.5 g/dL hemoglobin [Hb] change between Weeks 12/24). Correlation
with the EQ-5D visual analog scale (VAS) and “Usual Activity” domain score was used to assess concurrent validity.
Clinical validity was evaluated using a case-control method to link spontaneously reported fatigue and anemia
adverse events (AEs) during the study to FSS scores.
Results: FSS total scores demonstrated good reliability (Cronbach’s α: 0.95, 0.96; ICC: 0.74, 0.86 for PILLAR and
ASPIRE, respectively) and concurrent validity (correlation with EQ-5D VAS: -0.63, -0.66) with a monotonic relationship
between the EQ-5D “Usual Activities” item response and FSS. Clinical validity was confirmed by a significant difference
between cases and controls for fatigue AEs (p < 0.05); however, anemia defined by AE or Hb abnormalities was only
weakly related to FSS score. Analyses indicate that a change of 0.33–0.82 in mean FSS scores represents a meaningful
improvement in fatigue, and a one-point change is a conservative indicator of an important change in individual FSS
scores.
Conclusion: A difference of ≥0.7 in mean FSS scores can be considered a clinically important difference within groups
over time or between groups. A one-point change or less in individual FSS scores indicates a clinically relevant change
in fatigue.
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Fatigue is the most frequent symptom of chronic hepa-
titis C virus (cHCV) infection and also a common side
effect associated with interferon-based therapies for
cHCV infection [1-3]. Until recently, combination ther-
apy with peginterferon-α and ribavirin (PegIFN-α/RBV)
constituted the standard of care for HCV infection [4].* Correspondence: jscott51@its.jnj.com
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unless otherwise stated.However, direct-acting antivirals (DAA) such as NS3/4A
viral protease inhibitors when added to PegIFN-α/RBV
have significantly improved the rate of sustained viro-
logic response (SVR) rates compared with PegIFN-α/
RBV alone [5-9]. Interferon-free treatments in develop-
ment promise further reductions in treatment-induced
fatigue [10].
The DAA simeprevir is a potent, once-daily, oral HCV
NS3/4A protease inhibitor, recently approved for the
treatment of cHCV infection. In two Phase IIb studies ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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PIRE) with cHCV infection, simeprevir in combination
with PegIFN-α/RBV achieved significantly higher SVR
rates compared with PegIFN-α/RBV alone [11,12]. In
addition to efficacy and safety assessments, patients
enrolled in the PILLAR and ASPIRE trials completed the
Fatigue Severity Scale (FSS) in order to provide insight
into the severity and duration of fatigue associated with
the addition of simeprevir to PegIFN-α/RBV therapy. The
FSS was selected to measure fatigue in the simeprevir
trials because it is a brief, patient-reported outcome (PRO)
measure of the impact of disabling fatigue on daily func-
tioning in patients with chronic illness [13]. Initial valid-
ation of the FSS in patients with multiple sclerosis and
systemic lupus erythematosus demonstrated good psycho-
metric properties that were subsequently confirmed and
extended in cross-cultural studies and in a variety of other
chronic illnesses that have fatigue as a symptom or side
effect of treatment [14,15]. When validated in patients
with cHCV infection, the FSS produced a unidimensional
construct with a resulting total score that was both valid
and reliable [16]. The FSS has also been used to evaluate
patients’ experience of fatigue in cHCV infection, both as
a symptom of the disease and as an adverse event (AE) of
treatment [17]. Lower levels of fatigue were reported in
patients with SVR and an improvement in fatigue was
associated with discontinuation of HCV therapy. What
has yet to be determined is how to interpret the clinical
significance of changes in FSS scores, either for evaluation
of individual patients or group means in research [18].
Therefore, a key objective of this study was to establish
empirical guides for interpreting FSS scores for HCV
research.
Here we report the results of a psychometric analysis
conducted to evaluate the adequacy and interpretation of
FSS scores as a self-report measure of fatigue for clinical
trials in patients with cHCV infection. The analysis used
data from the PILLAR and ASPIRE trials in patients with
cHCV infection treated with simeprevir or placebo in
combination with PegIFN-α/RBV [11,12].
Methods
Data source
The PILLAR and ASPIRE studies were Phase IIb, multi-
center, randomized, double-blind, placebo-controlled stud-
ies conducted in treatment-naïve (PILLAR, NCT00882908)
or treatment-experienced (ASPIRE, NCT00980330) pa-
tients chronically infected with HCV [11,12]. The studies
were reviewed and approved by the institutional review
boards associated with each clinical site participating in the
PILLAR and ASPIRE protocols. Each patient provided
written informed consent prior to enrolling in the study. In
the PILLAR study, patients were randomized to one of five
treatments comprising simeprevir 75 or 150 mg/day for 12or 24 weeks or placebo, plus PegIFN-α/RBV. Patients in
the simeprevir arms could stop all treatment at Week 24
if HCV RNA testing indicated response to treatment
based on response-guided therapy (RGT) criteria (HCV
RNA <25 IU/mL at Week 4 and undetectable at Weeks
12, 16, and 20). Patients not meeting the RGT criteria
continued with PegIFN-α/RBV until Week 48, as did all
patients in the placebo control group (consistent with
approved dosing for PegIFN-α/RBV treatment). In the
ASPIRE study, patients with null or partial response or
relapse to prior PegIFN-α/RBV received simeprevir 100 or
150 mg/day for 12, 24, or 48 weeks plus PegIFN-α/RBV
for 48 weeks, or placebo plus PegIFN-α/RBV for 48 weeks.
Follow-up was 72 weeks in both studies. An external
physician reviewed HCV RNA levels throughout the
blinded study to limit exposure to treatment for patients
who experienced no viral response, viral breakthrough, or
on-treatment relapse [11,12]. Patients and investigators
remained blinded to the patient’s HCV RNA levels
through Week 48 of treatment.
Assessments
Patients completed the FSS and EuroQoL 5 dimension
(EQ-5D) questionnaires at baseline, and at regular
intervals during treatment and follow-up (FSS: Weeks 4,
12, 24, 36, 48, 60, 72; EQ-5D: Weeks 24, 48, 72). To
minimize missing data for analysis, study personnel were
instructed to review each completed questionnaire for
missing responses and ask patients to complete any missing
items before any other procedures were conducted during
the study visit.
The FSS questionnaire instructs patients to assign a score
of between 1 (completely disagree) and 7 (completely agree)
to each of 9 FSS items designed to rate the extent of fatigue
symptoms and their impact on patient functioning
(including motivation, exercise, physical functioning,
carrying out duties, and interfering with work, family, or
social life). Examples of the questions asked include
“exercise brings on my fatigue” and “my fatigue is very
debilitating”; a higher score indicates a higher degree of
fatigue for all items [18]. The standard scoring for the FSS
was used: the 9 items were averaged to produce an FSS
total score that ranges from 1 (no fatigue) to 7 (very severe
fatigue) with scores calculated for all patients who answered
at least half the FSS items. The FSS versions used in the
PILLAR and ASPIRE studies differed in terms of length of
recall period (i.e., patients were required to think back over
a period of 14 days in PILLAR compared with 7 days in
ASPIRE).
The EQ-5D is a self-administered questionnaire devel-
oped for measuring health status [19,20]. It comprises five
questions relating to five health dimensions (Mobility, Self
Care, Usual Activities, Pain/Discomfort, and Anxiety/
Depression). Patients rate their current health status on
Table 1 Definition of clinical sub-groups by absolute
hemoglobin level [25]
Hemoglobin Female (g/dL) Male (g/dL)
Normal >12 >13.5
Mild (Grade 1) 11−12 12.5−13.5
Moderate (Grade 2) 9.5−10.9 10.5−12.4
Severe/life-threatening (Grade 3/4) <9.5 <10.5
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level 2, some problems; level 3, extreme problems). The
EQ-5D also includes a visual analog scale (VAS) which
assesses overall health status on a scale of 0–100, with a
score of 100 representing perfect health and a score of 0
the worst imaginable health status. For the FSS valid-
ation, two EQ-5D scores were used: the “Usual Activities”
score from the EQ-5D descriptive system and the EQ-5D
VAS.
During both studies, the investigators recorded the
type, severity, and duration of any AEs spontaneously
reported by patients. Fatigue and anemia AEs were
identified using MedDRA preferred terms (“fatigue”,
“aesthenia”, or “asthenia”; and “anaemia”, “haemoglobin
decreased”, or “haemolytic anaemia”, respectively).
Blood samples were collected for determination of
hemoglobin and plasma HCV RNA concentrations at
baseline, Weeks 4 and 12, and then at 12-weekly inter-
vals up to and including Week 72. For the purposes of
the psychometric validation, patients were deemed no
longer infected with HCV if they achieved an undetect-
able HCV RNA viral load at end of treatment (EOT)
and at 24 weeks post treatment (SVR24).
Analyses
Data from the PILLAR and ASPIRE studies were analyzed
separately because the FSS recall periods were different
for the two studies. Within each study, data were pooled
across treatment groups. All analyses were conducted
using SAS software (Statistical Analysis System, Version
9.2). The threshold for statistical significance was p < 0.05
for all comparisons.
Distribution
The proportion of patients for whom the FSS total score
could be calculated and the mean FSS total scores were
determined. Percent of missing responses was calculated
for each FSS item. Floor or ceiling effects at baseline
were determined to assess the proportions of patients
with the minimum possible (floor) or maximum possible
(ceiling) values for individual FSS items and FSS total
scores, and were considered present when more than
14.3% (calculated as 100/7, reflecting the 7 possible
response categories for the FSS) of patients achieved
these values. Analysis of floor and ceiling effects
provides an indication of the ability of a PRO instrument
to detect changes in a study population. If floor or
ceiling effects are too pronounced, mean scores will be
very high (ceiling) or very low (floor), making it difficult
to detect changes over time.
Reliability
Internal consistency reliability was assessed to evaluate
the unidimensionality of the FSS total score, includingthe impact of item deletion. This was determined by
calculating Cronbach’s coefficient α, with good internal
consistency met if Cronbach’s α exceeded the widely
accepted cut-off of 0.7 [21,22]. The impact of item
removal on internal consistency reliability was examined
by calculating Cronbach’s α after removal of each item
from the total FSS score. An increase in Cronbach’s α
after item deletion suggests that the item did not fit well
with the total score.
Test-retest reliability that measures the degree to
which an instrument produces similar scale scores at dif-
ferent points in time in “stable” patients was evaluated
by calculating the intraclass correlation (ICC) [23]. The
ICC was determined by comparing change in FSS total
score at two different time points (Weeks 12 and 24) in
a sub-group of stable patients, defined as individuals
with <0.5 g/dL absolute change (improvement or wors-
ening) in hemoglobin level between Weeks 12 and 24.
An ICC value of at least 0.7 is considered evidence of ac-
ceptable test-retest reliability [24]. Pearson’s correlations
were also calculated. The ICC is the preferred estimate
of test-retest reliability over the Pearson’s correlation as
it adjusts for any systematic mean shift that may be
present between visits. If a mean shift is absent, the ICC
and Pearson’s correlation are equivalent.
Clinical validity
Known-groups validity assesses the extent to which scores
are linked to a patient’s known health state or status based
on clinical parameters that classify patients into groups.
This was first evaluated by comparing FSS total scores and
FSS change from baseline across four clinical sub-groups
defined according to absolute hemoglobin level at EOT
(normal, mild [Grade 1], moderate [Grade 2], severe/
life-threatening [Grade 3/4]) [Table 1] [25].
Known-groups validity was also assessed based on
SVR rate 24 weeks post treatment (SVR24) and on AE
reports of anemia and fatigue. Both actual FSS total
scores and change from baseline in FSS total score at
the end of follow-up were compared for patients with
and without SVR24 to evaluate the change in fatigue
associated with achieving an undetectable HCV viral
load. The first (or worst severity rated if more than one)
fatigue or anemia AE that occurred during the FSS recall
period (PILLAR: 2 weeks; ASPIRE 1 week) was recorded
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control method was employed whereby a control was se-
lected from among patients who did not experience the
relevant AE during the recall period, matching based on
gender, age, and ethnicity. FSS scores at baseline and at
the visit at which the worst AE occurred were reported,
and change from baseline FSS scores were compared for
cases versus controls.
Student t-tests were used for tests involving two groups,
and one-way analysis of variance was used for tests involv-
ing three or more groups. Analyses were only performed
for categories that included at least 20 patients in the
smallest sub-group. Nonparametric methods were used if
normality assumptions were not met.
Concurrent validity
Concurrent validity is used to measure the correlation
between two different PRO instruments that measure
the same or related constructs. Using 24-week data, FSS
total score was compared between groups, defined by
response category for the EQ-5D “Usual Activities” item.
A monotonic relation was pre-specified (i.e., lower FSS
scores in patients with no problems versus some prob-
lems on the “Usual Activities” domain, and the highest
scores in patients unable to perform “Usual Activities”).
In addition, the correlation between FSS total score and
overall health status, as measured by the EQ-5D VAS,
was assessed based on 24-week data. A moderate and
negative correlation was pre-specified based on the fact
that a high VAS score represents good health and a high
FSS total score indicates high fatigue levels.
Responsiveness
Responsiveness measures the ability of an instrument to
detect and measure change over time when underlying
change has occurred in the construct being measured. In
the planned preliminary analysis, clinically important
changes in hemoglobin (1.0 g/dL change between visits)
were proposed as a means of classifying patients as “im-
proved” (at least a one-grade improvement in hemoglobin-
defined anemia) or “worsened” (at least a one-grade change
in hemoglobin-defined anemia). Different time points were
used in the FSS responsiveness analyses to evaluate im-
provement (EOT versus end of study [EOS], i.e., Week 72)
and worsening (baseline versus Week 24). This was neces-
sary because the PILLAR and ASPIRE study protocols
excluded patients with anemia at baseline (defined as
hemoglobin <12 g/dL or <13.5 g/dL for females and males,
respectively).
The second evaluation of responsiveness tested against
the ability of the FSS to detect change in overall health sta-
tus using the EQ-5D VAS, from baseline to Week 24
(“worsening”) and from EOT to EOS (“improvement”).
Change groups were defined by a 10-point change on theVAS (reflecting 10% of the possible range for the VAS).
Finally, responsiveness was evaluated using shift in the
EQ-5D “Usual Activities” domain score from baseline
to Week 24 (“worsening”) and from EOT to EOS
(“improvement”).
Minimal important difference
Minimal important difference (MID) provides a guide
for interpreting the minimum change in a score. Distri-
butional and anchor-based methods can be used for
determining MID, with both producing generally similar
results [26]. A distributional estimate of the MID was
determined using the standard error of measurement
(SEM) based on reliability of the FSS questionnaire
(SEM = standard deviation [SD] × √[1-reliability]). The
SEM is equivalent to ½ SD when reliability is equal to
0.75 and decreases as reliability increases. The ICC has
been proposed as the most stable estimate to use in the
calculation of the SEM [22]. For the anchor-based ap-
proach, the pre-specified analysis proposed a responder
operating curve (ROC) analysis to establish the MID
within-group change in FSS total score based on the
changes in FSS scores that occur with clinically important
changes in hemoglobin.Results
Patients
A total of 386 treatment-naïve patients from the PILLAR
study and 462 treatment-experienced patients from the
ASPIRE study were included in the validation analysis.
In both studies, the majority of patients (>90%) were
Caucasian. Mean age was 44.0 years in the PILLAR
study and 48.9 years in the ASPIRE study, and 55.2%
and 67.3% of patients, respectively, were male [Table 2].
Baseline FSS item and total score distribution and
floor−ceiling effects
The percentage of missing FSS item responses was
low (≤0.4%) in both studies. A ceiling effect was
observed for item 1 of the FSS (PILLAR 31%; ASPIRE
26%) indicating complete agreement with the state-
ment “my motivation is lower when I’m fatigued”.
The remaining 6 items had moderate to large floor
effects (PILLAR 20.4−43.3%; ASPIRE 17.8−42.1%),
endorsing the lowest response category, indicative of
low levels of fatigue.
Baseline FSS total scores were available for 245 of
the 386 patients in the PILLAR study (mean [SD]:
3.28 [1.58]) and for 449 of the 462 patients (mean
[SD]: 3.34 [1.65]) in the ASPIRE study [Figure 1].
Only 4.9% of patients had the lowest possible score
(floor) and 1.2% had the highest possible score (ceiling)
in the PILLAR study. The corresponding results for the
Table 2 Patient characteristics at baseline
Treatment-naïve (PILLAR) Treatment-experienced (ASPIRE)
All patients (ITT) Patients with baseline FSS
and ≥1 follow-up
All patients (ITT) Patients with baseline FSS
and ≥1 follow-up
N = 386 N = 241 N = 462 N = 446
Sex, n (%) N = 386 N = 241 N = 462 N = 446
Male 213 (55.2) 136 (56.4) 311 (67.3) 301 (67.5)
Female 173 (44.8) 105 (43.6) 151 (32.7) 145 (32.5)
Age, mean, SD (years) 44.0 (11.81) 45.9 (10.37) 48.9 (10.36) 48.9 (10.37)
Race, n (%) N = 386 N = 241 N = 462 N = 446
Caucasian 362 (93.8) 225 (93.4) 428 (92.6) 414 (92.8)
Non-Caucasian 24 (6.2) 16 (6.6) 34 (7.4) 32 (7.2)
Region, n (%) N = 386 N = 241 N = 462 N = 446
North America 82 (21.2) 52 (21.6) 120 (26.0) 113 (25.3)
Latin America 0 0 0 0
Europe/Israel 262 (67.9) 147 (61.0) 313 (67.7) 306 (68.6)
Asia 42 (10.9) 42 (17.4) 29 (6.3) 27 (6.1)
HCV RNA, mean (log10 IU/mL) 6.5 (0.61) 6.5 (0.64) 6.5 (0.57) 6.5 (0.56)
Genotype, n (%) N = 383 N = 239 N = 455 N = 439
1a 173 (45.2) 122 (51.0) 188 (41.3) 178 (40.5)
1b 208 (54.3) 115 (48.1) 262 (57.6) 257 (58.5)
Other 2 (0.5) 2 (0.8) 5 (1.1) 4 (0.9)
METAVIR score, n (%) N = 386 N = 241 N = 455 N = 439
F0–F2 332 (86.0) 203 (84.2) 286 (62.9) 278 (63.3)
F3 53 (13.7) 38 (15.8) 86 (18.9) 83 (18.9)
F4 1 (0.3) 0 83 (18.2) 78 (17.8)
Baseline PRO (mean)
FSS total score 3.3 (1.58) 3.3 (1.57) 3.3 (1.65) 3.3 (1.65)
EQ-5D VAS 82.4 (15.28) 81.8 (15.75) 80.4 (16.47) 80.4 (16.42)
EQ-5D VAS European Quality of Life 5 dimension questionnaire visual analog scale, FSS Fatigue Severity Scale, HCV hepatitis C virus, ITT intent to treat,
PRO patient-reported outcome, SD standard deviation.
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gether, these findings confirmed that the floor and ceiling
effects were of no concern in either study.Internal consistency
Cronbach’s coefficient α was above the cut-off of 0.7 for
FSS at baseline, indicating high internal consistency in
both studies (PILLAR 0.96; ASPIRE 0.96) [Table 3]. For
all except the first FSS item, Cronbach’s α decreased
slightly after deletion of each item, confirming that the
items contribute to the total score and belong to the
scale. The fact that deletion of the first item did not
reduce Cronbach’s α suggests that it does not contribute
to the FSS total score.Test-retest reliability
ICC values for the PILLAR and ASPIRE studies (0.74
and 0.86, respectively) met the established criteria fortest-retest reliability. Results also indicated no mean shift
(ICC compared with Pearson’s correlation) in FSS total
score [Table 3]. A total of 159 patients in the PILLAR study
and 147 patients in the ASPIRE study were categorized as
stable. Mean (SD) total FSS score at Weeks 12 and 24
were very similar (PILLAR: 4.3 [1.49] and 4.3 [1.56],
respectively, p = 0.652; ASPIRE: 4.2 [1.70] and 4.2 [1.68],
respectively, p = 0.635).Clinical validity
In both the PILLAR and ASPIRE studies, patients
with normal hemoglobin levels or mildly suppressed
hemoglobin at EOT had similar mean FSS total scores,
while patients with abnormal hemoglobin, indicating
moderate to severe anemia, had higher (worse) fatigue
scores [Table 4]. Change in FSS score from baseline in-
creased as expected as hemoglobin decreased, achieving
statistical significance (moderate/severe versus normal,
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FSS Fatigue Severity Scale, ICC intraclass correlation.
aTest-retest reliability was calculated using data from Week 12 and Week 24,
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Figure 1 Summary of available data for the FSS total score. FSS total score was based on the mean of the 9-item score. If the number of
missing items was <4, the FSS total score was the mean of the non-missing items; if 4 or more items were missing, the total score was set to
missing. The PILLAR study was the first simeprevir trial to include PRO endpoints. Sites that enrolled the first patients did not have appropriate
language translations of the PRO instruments for their patients to complete at their baseline visit, hence the low patient numbers at baseline in
PILLAR (n = 245). Some of these patients subsequently completed PRO instruments at post-baseline visits. BL baseline, FSS Fatigue Severity Scale,
ITT intent to treat, PRO patient-reported outcome.
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change between hemoglobin categories in the ASPIRE
study.
Patients with fatigue AEs had consistently higher FSS
scores than control patients in both the PILLAR and
ASPIRE studies [Table 4; Figure 2c and d]. Although both
the case and control patients experienced a worsening of
their total FSS score from baseline, the deterioration was
more pronounced among patients with fatigue versus
controls and reached statistical significance in both
studies. FSS total scores were not significantly different for
patients with and without anemia AEs.
Patients who achieved SVR24 had lower mean FSS total
scores compared with patients who did not in both the
Table 4 Validity of the FSS
FSS scores Actual score at time of clinical outcome Change from baseline to clinical event
Treatment-naïve Treatment-experienced Treatment-naïve P value Treatment-experienced P value
(PILLAR) (ASPIRE) (PILLAR) (ASPIRE)
Mean (SD) Mean (SD) Mean CFB (SD) Mean CFB (SD)
SVR24
Yes 2.7 (1.59) 3.0 (1.63) -0.6 (1.41) -0.4 (1.42)
No 3.5 (1.83) 3.6 (1.80) 0.3 (1.28) *** 0.4 (1.50) ***
Hemoglobin (EOT)a
Normal 4.3 (1.76) 4.3 (1.77) 0.8 (1.54) (comparator) 1.0 (1.56) (comparator)
Mild anemia 4.3 (1.67) 4.2 (1.73) 1.2 (1.67) n.s. 0.9 (1.53) n.s.
Moderate/severe anemia 4.7 (1.55) 4.5 (1.73) 1.5 (1.56) * 1.1 (1.62) n.s.
Anemia AE
Case 4.5 (1.79) 4.8 (1.70) 1.2 (1.76) 1.1 (1.72)
Control 4.2 (1.73) 4.4 (1.74) 1.0 (1.38) n.s. 1.0 (1.38) n.s.
Fatigue AE
Case 4.4 (1.58) 4.5 (1.59) 1.1 (1.45) 0.9 (1.35)
Control 3.8 (1.67) 3.5 (1.67) 0.5 (1.49) * 0.4 (1.26) ***
EQ-5D “Usual Activities”
“No problems” 3.3 (1.31) 3.4 (1.51) 0.6 (1.29) (comparator) 0.6 (1.38) (comparator)
“Some problems” 5.2 (1.23) 5.4 (1.19) 1.6 (1.64) *** 1.5 (1.45) ***
“Cannot perform”b 6.5 (0.48) 6.5 (1.15) 2.2 (1.97) ** 1.4 (1.69) *
AE adverse event, CFB change from baseline, EOT end of treatment, EQ-5D European Quality of Life 5 dimension questionnaire, FSS, Fatigue Severity Scale,
n.s. not significant, SD standard deviation, SVR24 sustained virologic response rate 24 weeks post treatment.
*p < 0.05; **p < 0.01; ***p < 0.001.
aClinical groups were defined as normal: >12 g/dL (female), >13.5 g/dL (male); mild (Grade 1) 11–12 g/dL (female), 12.5–13.5 g/dL (male); moderate (Grade 2)
9.5–10.9 g/dL (female), 10.5–12.4 g/dL (male); severe/life-threatening (Grade 3/4) <9.5 g/dL (female), <10.5 g/dL (male).
bThe “cannot perform” group included low numbers of patients: PILLAR, n = 8; ASPIRE, n = 16.
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baseline FSS total scores indicated that patients with
SVR24 improved by 0.6 (PILLAR) or 0.4 points (ASPIRE)
while patients without SVR worsened by 0.3 and 0.4 points,
respectively (p < 0.001 for between-group comparisons in
both studies).
Concurrent validity
In both the PILLAR and ASPIRE studies, patients grouped
by responses to the EQ-5D “Usual Activities” item at
Week 24 showed the predicted monotonic relation with
total FSS score [Table 4]. Patients with “no problems”
performing “Usual Activities” had lower mean FSS total
scores than patients with “some problems”; patients in the
“cannot perform usual activities” category had the highest
FSS scores indicating the most severe fatigue as expected
[Figure 2a and b]. Compared with the “no problems”
group, the differences in change from baseline FSS scores
were significant for the “some problems” group (p < 0.001
both studies) and the “cannot perform” group in both
studies (PILLAR, p = 0.002; ASPIRE, p = 0.021). Of note,
change from baseline in FSS total score was monotonic in
the PILLAR study but not in the ASPIRE study; this mayhave been attributable to high baseline FSS total scores in
the “cannot perform” group in the ASPIRE study, possibly
reflecting the greater proportion of patients in ASPIRE
with advanced liver fibrosis. The correlation between the
FSS total score and EQ-5D VAS was moderate and in the
direction expected (PILLAR, r = -0.63; ASPIRE, r = -0.66).
Responsiveness
The FSS showed good responsiveness as summarized in
Table 5; however, responsiveness to changes in anemia
produced weak results. Patients who “worsened” based
on hemoglobin abnormalities used to define anemia (Grade
1 − 4) showed a greater mean increase in FSS total score
from baseline to Week 24 (denoting worsened fatigue)
compared with the “not worsened” group in both studies.
The differences between groups in both studies failed to
reach statistical significance using parametric testing,
although statistical significance was achieved using the
Wilcoxon rank-sum test in the PILLAR study (p < 0.05).
Improvement in FSS total score from EOT to EOS was
significantly greater in the “improved” patient group (at
least a one-category improvement in hemoglobin) than in















































































Figure 2 Validity of the FSS. Mean change from baseline at EOT or event; a) and b) patients with no problems, some problems or patients
who could not perform the EQ-5D “Usual Activities” dimension at EOT; c) and d) patients (cases) with fatigue AEs versus control patients. p values
versus “no problem” (a and b) or versus “control” (c and d). AE adverse event, EOT end of treatment, EQ-5D European Quality of Life 5 dimension
questionnaire, FSS Fatigue Severity Score.
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“improved” versus “unimproved” group in the ASPIRE
study.
In the responsiveness assessment based on important
change in the EQ-5D VAS, mean change from baseline to
Week 24 in FSS total score was significantly worse in the
“worsened” group (≥10-point worsening on the EQ-5D
VAS) compared with the “not worsened” group (<10-point
improvement/worsening on the EQ-5D VAS) (p < 0.001
for both studies). Similarly, improvement in FSS total
score from EOT to EOS in the “improved” group
(≥10-point improvement in EQ-5D VAS) was significantly
greater than that observed in the “unimproved” group
(p < 0.001 for both studies) [Table 5].
Finally, in the responsiveness assessment based on groups
defined by category shift in the EQ-5D “Usual Activities”
response, mean change from baseline to Week 24 in FSS
total score was significantly worse in the “worsened” group(patients who shifted from “no problems” to “some
problems”) compared with the “not worsened” group
(p < 0.001 for both studies). Similarly, improvement in FSS
total score from EOT to EOS in the “improved” group
(patients who shifted from “some problems” to “no
problems”) was significantly greater than that observed in
the “unimproved” group (p < 0.001 for both studies)
[Table 5].
Minimal important difference
Due to inadequate numbers of patients with the defined
point changes in hemoglobin, the planned ROC analysis
was not performed. Distribution-based estimates of the
MID based on the PILLAR study suggested that an
observed group mean change in FSS score of between 0.34
and 0.79 was indicative of an interpretable and meaningful
improvement in fatigue. Similar findings were reported for
the ASPIRE study (mean change 0.33 − 0.82).
Table 5 Responsiveness of the FSS score
FSS scores Treatment-naïve Treatment-experienced
(PILLAR) (ASPIRE)
Mean CFB (SD) P value Mean CFB (SD) P value
Hemoglobin
Baseline to Week 24a
Worsened 1.3 (1.61) 1.0 (1.47)
Not worsened 0.8 (1.48) n.s. 0.8 (1.51) n.s.
EOT to 24-wk FUb
Improved -1.6 (1.73) -1.3 (1.55)
Unimproved -1.1 (1.38) ** -1.0 (1.52) n.s.
EQ-5D VAS
Baseline to Week 24
Worsened 1.6 (1.61) 1.5 (1.47)
Not worsened 0.5 (1.33) *** 0.5 (1.33) ***
EOT to 24-wk FU
Improved -2.1 (1.62) -1.6 (1.65)
Unimproved -0.8 (1.37) *** -0.7 (1.23) ***
EQ-5D “Usual Activities”
Baseline to Week 24
“No problems” to “some problems” 1.90 (1.51) 1.72 (1.44)
Not worsened 0.52 (1.35) *** 0.57 (1.34) ***
EOT to 24-wk FU
“Some problems” to “no problems” -2.27 (1.68) -2.05 (1.53)
Unimproved -0.98 (1.30) *** -0.80 (1.35) ***
CFB change from baseline, EOS end of study, EOT end of treatment, EQ-5D VAS, European Quality of Life 5 dimension questionnaire visual analog scale,
FSS Fatigue Severity Scale, FU follow-up, n.s. not significant, SD standard deviation.
**p < 0.01; ***p < 0.001.
a“Worsened” was defined, using data from baseline and Week 24, as those patients with at least a Grade 1 change in anemia based on hemoglobin levels.
b“Improved” was defined, using data from EOT and EOT + 24 weeks (EOS, 72 weeks), as at least a Grade 1 improvement in anemia based on hemoglobin levels.
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This analysis used data from two randomized, double-
blind, placebo-controlled studies conducted in treatment-
naïve and -experienced patients with cHCV infection to
reconfirm that the FSS is a valid, reliable, and responsive
measure of fatigue for use in HCV treatment trials. An
important and unique aspect of this study was the identifi-
cation of the degree of change in the FSS that can be con-
sidered clinically meaningful.
At baseline, a floor effect was observed for 6 of the 7
FSS items. Although the PILLAR and ASPIRE studies
enrolled patients who potentially experienced some
fatigue at baseline as a result of cHCV infection, much of
the fatigue observed in these trials was attributable to side
effects of treatment. Therefore, it was not unreasonable
for large floor effects, indicative of low levels of fatigue, to
exist at baseline. Large floor effects would not interfere
with the measurement goal of evaluating increased fatigue
but could make it difficult to evaluate improvements in
fatigue, potentially attenuating any observed benefit ofSVR on fatigue. Floor–ceiling effects for the FSS total
score were minimal.
Internal consistency reliability of the FSS was very good.
The item level deletion results suggested that the first FSS
item (“my motivation is lower when I am fatigued”) did
not add consistent information and could potentially be
removed from the scale for future work. This finding was
not unexpected given that the wording of item 1 is differ-
ent from that of the other items, being more general
rather than directly evaluating the patient’s current state
of fatigue. Test-retest reliability surpassed the pre-
specified criteria of 0.70 for both studies. As predicted, the
FSS had moderate negative correlations with the EQ-5D
VAS and showed a monotonic relationship with the
EQ-5D “Usual Activities” item, with results consistent
between the two studies.
Results from clinical validity analyses relating the FSS to
hemoglobin levels were mixed. In general, total FSS scores
were similar in patients with normal or mild hemoglobin
abnormalities. This is consistent with current descriptions
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moderate or high (at least Grade 2) hemoglobin levels
differed from patients without significantly reduced
hemoglobin levels, with a highly significant effect in the
PILLAR study and a moderate, non-significant effect in
the ASPIRE study.
Reports of anemia AEs were only weakly related to FSS.
There was a non-significant trend towards a greater
change in total FSS score from baseline to the recall
period for the reported event for patients with anemia
AEs compared with controls in both studies. In contrast,
there was a strong association between reports of fatigue
AEs and FSS, with change in total FSS score from baseline
to the recall period for the event significantly higher for
cases versus controls in both studies.
The FSS also had a strong relation with SVR in both
studies, with patients achieving SVR at study end having
significantly lower FSS total scores than patients without
SVR. Our findings are consistent with the recommenda-
tions provided by Sarkar et al. in their report of the fatigue
results from the Virahep-C study [2]. Based on a simple
VAS measure of fatigue collected before, during, and after
treatment for HCV, the authors reported that the presence
and severity of fatigue ultimately declined in patients with
sustained clearance of HCV. They commented that their
findings indicated that HCV therapy can lead to significant
and sustained improvement in clinical symptoms, and that
the measurement of fatigue using VAS is successful in
capturing these changes, with improvements in fatigue
being most convincing in those patients with moderate to
severe levels of fatigue at baseline. The authors concluded
that those patients with relatively nonsignificant biochemical
or histologic disease, but with troublesome symptoms such
as fatigue, should be considered for antiviral therapy [2].
The responsiveness analysis indicated that the FSS score
measures change where change in fatigue-related concepts
exists; however, responsiveness to changes in anemia
produced weak results. While we expected a relationship
between self-reported fatigue and anemia AEs, other causes
for fatigue have been suggested in the literature, including
increased HCV viremia in the brain and central nervous
system [29]. However, at the time of writing no studies have
definitively linked central nervous system levels of HCV
viremia with patient-reported fatigue. A multivariate ap-
proach could potentially uncover the interactive relationship
of anemia as a treatment-emergent AE and SVR in predict-
ing fatigue, and may be a fruitful area of future research.
In addition to understanding whether a PRO instrument
can detect change, it is also essential to understand the
meaning associated with the change. The point at which a
change score becomes important has been characterized as
the MID. The MID is often misunderstood to represent the
point difference that must be present between treatment
groups in order for a difference to be considered clinicallymeaningful. Instead, the MID should be considered to be a
within-group phenomenon [30] and any between-group
effect size should actually be smaller than the MID [31].
During the design of a study, clinical knowledge of the indi-
cation and the expected effect of both treatment and
control should guide estimates of effect size. For example,
one might expect a very small effect between a treatment
and an active comparator, and a larger effect between
placebo and treatment. The accurate estimation of sample
size to test a certain effect size takes into account the preci-
sion of the endpoint. On this basis, the MID should be used
to guide decisions about change within a group that can be
considered meaningful. A clinically meaningful between-
groups effect size is not an artifact of the instrument in use,
but instead should be determined based upon clinical and
statistical considerations. As indicated in the FDA’s PRO
Guidance [32], these methods are not appropriate for deter-
mining the precise point at which a score change indicates
clinical significance but are useful for evaluating the
meaning of an observed score change.
The MID or the meaning associated with changes in FSS
scores was assessed using distributional estimates. Results
from both studies suggest that an interpretable and
meaningful improvement in fatigue occurs when there is
an observed-group mean change in FSS total score of be-
tween 0.33 and 0.82. Although the planned anchor-based
analyses could not be performed because of insufficient
sample with significantly suppressed hemoglobin levels,
additional information on the importance of change scores
can be gained through evaluation of the analyses involving
the EQ-5D and fatigue AE events as previously discussed.
Considered together, the results support a one-point
change in an individual’s FSS score as a reasonable and
appropriate responder definition. These results have been
confirmed in a pooled analysis of three simeprevir Phase III
clinical trials [33].
Together these results extend our understanding of the
utility and interpretation of the FSS for research in patients
with cHCV. The earlier study by Kleinman et al. used
screening and baseline visits to evaluate reliability and
convergent validity of the FSS with other outcomes [18].
Our study adds to this by showing the link between FSS
scores and clinicians’ ratings for fatigue and anemia, but also
hemoglobin abnormalities and SVR. The current study
provides guides that can be used to evaluate group means
or individual scores that have been confirmed using data
from over 800 patients, including treatment-naïve and
treatment-experienced patients, during treatment for cHCV.
Future studies using the FSS can better estimate the statis-
tical power required for evaluating fatigue effects given these
findings. Our findings suggest that the FSS may also be used
to evaluate whether fatigue levels warrant initiation of HCV
treatment and to ensure treatment-emergent fatigue is
detected and managed successfully.
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These analyses indicate the FSS is a valid and reliable PRO
tool appropriate for use in clinical trials involving patients
with HCV infection. The current results support a re-
sponder definition of one point on the FSS score; however,
cumulative response distributions at critical time points are
recommended to aid interpretation of parametric results.
Further work is required to understand the relationship
between fatigue, anemia, and hemoglobin abnormalities,
particularly in treatment-experienced HCV patients under-
going retreatment; this will likely require inclusion of a large
patient population and a multivariate approach to separate
out disease effects, positive response to treatment, and
adverse effects of treatment.
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